VISTA is an important immune modulatory receptor that is gaining attention in cancer immunotherapy. VISTA exerts its suppressive effects on T cell activity by binding to their respective ligands on T cells, potentially influencing the immune evasion mechanisms of tumors. Studies have shown that VISTA is expressed in a variety of cancers, including melanoma, pancreatic cancer, and prostate cancer, and its expression levels are closely related to the immunosuppressive state of tumors.